Please assess the completion status of the following clinical trial:

Trial Title: Doxycycline in Human Pulmonary Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Healthy Volunteers 10 volunteers will be recruited comprising 5 females and 5 males.~Inclusion criteria:~1. No known medical conditions~2. Aged 21 years to less than 70.~Exclusion criteria:~1. Unable to give informed consent~2. Prisoners~3. Pregnancy or nursing~4. On medication or oral contraceptives~5. Any concurrent illness, such as influenza~TB patients~Inclusion criteria: Patients should meet all criteria~1. Patients receiving ≤ 7 days of TB treatment or about to start standard combination TB treatment~2. Confirmed pulmonary TB with positive acid-fast bacilli smear and/or positive TB GeneXpert test and/or culture results~3. Chest radiograph demonstrating pulmonary involvement~4. Aged 21 years to less than 70~Exclusion criteria:~1. HIV co-infection~2. Previous pulmonary TB~3. Severe, pre-existing lung disease such as pulmonary fibrosis, bronchiectasis, Chronic obstructive pulmonary disease and lung cancer~4. Pregnant or breast feeding~5. Allergies to tetracyclines~6. Patients on retinoic acid, neuromuscular blocking agents and pimozide which may increase risk of drug toxicity~7. Autoimmune disease and/or on systemic immunosuppressants~8. Unable to provide informed consent~9. Haemoglobin \< 8 g/dl~10. Creatinine 2 times upper limit of normal (ULN)~11. Alanine transaminase \>3 times ULN~12. Use of any investigational or non-registered drug, vaccine or medical device other than the study drug within 182 days preceding dosing of study drug, or planned use during the study period~13. Enrolment in any other clinical trial involving a systemic drug or intervention involving the lung~14. Evidence of severe depression, schizophrenia or mania~15. Principal investigator assessment of lack of willingness to participate and comply with all requirements of the protocol, or identification of any factor felt to significantly increase the participant's risk of suffering an adverse outcome

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Doxycycline (Type: EXPERIMENTAL): Doxycycline 100 mg twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently doxycycline will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently placebo will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician

Based on this trial design, predict the completion outcome and termination type (if applicable).